Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
No Result
View All Result
HealthNews
No Result
View All Result
Home Medicine

Noninferiority of Once-Weekly Insulin Icodec Demonstrated in Two T2D Trials

admin by admin
July 30, 2022
in Medicine


Treatment with once-weekly insulin icodec was associated with noninferior reductions in HbA1c in adults with type 2 diabetes when compared with daily injections of insulin degludec and insulin glargine, according to results from two phase 3a trials.

The 26-week, double-blind ONWARDS 3 trial compared the efficacy and safety of insulin icodec to insulin degludec with noninsulin antidiabetic treatment in 588 adults with type 2 diabetes who had not previously been treated with insulin. Patients received either insulin icodec subcutaneously (SC) once weekly or insulin degludec SC once daily for 26 weeks. The primary endpoint was the percent change in HbA1c.

Results from ONWARDS 3 showed that treatment with insulin icodec met the primary endpoint demonstrating noninferiority in reducing HbA1c at week 26 compared with insulin degludec. Patients treated with insulin icodec achieved a superior reduction in estimated HbA1c of 1.57%, from an overall baseline HbA1c of 8.5%, compared with 1.36% for insulin degludec (estimated treatment difference, -0.21%).


Continue Reading

The 26-week ONWARDS 4 trial compared the efficacy and safety of insulin icodec to insulin glargine in combination with mealtime insulin (insulin aspart given 2 to 4 times daily) in 582 adults with type 2 diabetes. Patients received either insulin icodec SC once weekly or insulin glargine SC once daily for 26 weeks. The primary endpoint was the percent change in HbA1c.

In ONWARDS 4, treatment with insulin icodec met the primary endpoint demonstrating noninferiority in reducing HbA1c at week 26 compared with insulin glargine. Patients treated with insulin icodec achieved a reduction in estimated HbA1c of 1.16%, from an overall baseline HbA1c of 8.3%, compared with 1.18% for insulin glargine (estimated treatment difference, 0.02%).

Insulin icodec was found to be safe and well tolerated in both trials. No statistically significant differences in estimated rates of severe or clinically significant hypoglycemia were observed between the treatment groups.

“We are very pleased to see that the results from ONWARDS 3 and 4 reinforce the potential of once-weekly insulin icodec to simplify basal insulin therapy for people with type 2 diabetes as an ideal starter insulin and as an attractive option in combination with mealtime insulin,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “We are now looking forward to sharing the results from ONWARDS 5, the last remaining trial in the ONWARDS program in the second half of this year.”

The ONWARDS clinical development program consists of six phase 3a global clinical trials.

Reference

Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3. News release. Novo Nordisk. Accessed July 29, 2022. https://www.globenewswire.com/news-release/2022/07/29/2488672/0/en/Novo-Nordisk-achieves-primary-objectives-of-ONWARDS-3-and-4-trials-with-once-weekly-insulin-icodec-demonstrating-superior-reduction-in-HbA1c-vs-insulin-degludec-in-ONWARDS-3.html

This article originally appeared on MPR



Source link

Advertisement Banner
Previous Post

Roundup: HealthPlix launches drug-drug interaction feature, Intellect partners with Swiss Life and more briefs

Next Post

Researchers Identify Symptoms That Are Different From Previous Outbreaks

Next Post

Researchers Identify Symptoms That Are Different From Previous Outbreaks

Discussion about this post

Recommended

Broccoli Compound May Solve Antibiotic Resistance Problem

5 days ago

Who Should Get Vaccinated Against Monkeypox?

1 month ago

Don't Miss

Celebrating Health for 25 Years

August 8, 2022

Cherry Tomato Salad | Mark’s Daily Apple

August 8, 2022

Digital gastrointestinal care startup Salvo Health launches with $10.5M

August 8, 2022

Natural Language Processing and Digital Health Transformation, Health News, ET HealthWorld

August 8, 2022

© 2022 Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.